Editors' Picks
Eli Lilly Forays Into RNA Editing, Betting More than a Billion Dollars on ProQR’s Technology
2021-09-09
Mu COVID Variant Could Potentially Escape Immunity But Delta is Still “Most Concerning”, WHO Says
2021-09-08
Poseida Presents Encouraging Preliminary Data for Autologous CAR-T Candidate Against Solid Tumors
2021-08-31
Current Challenges and Future Opportunities of Artificial RNA Editing – An Interview with Professor Toshifumi Tsukahara
2021-08-26
Addressing The Global Need for Biosimilars: Current Trends, Expectations and Real World Experiences
2021-08-26
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115